New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
07:50 EDTGWPHGW Pharmaceuticals shares attractive ahead of data, says Leerink
After meeting with management, Leerink says is continue to view shares of GW Pharmaceuticals as attractive here ahead of additional Epidiolex data readouts and the commencement of pivotal trials in the second half of 2014. The firm reiterates an Outperform rating on the stock with a $110 price target.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:08 EDTGWPHGW Pharmaceuticals initiates first Phase 3 pivotal trial for Epidiolex
GW Pharmaceuticals announces it has initiated the Phase 3 part of a Phase 2/3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW anticipates that top-line data from this trial will be available around the end of 2015.
March 26, 2015
08:30 EDTGWPHGW Pharmaceuticals risk/reward favorable into data, says Leerink
Leerink says the risk/reward on shares of GW Pharmaceuticals is favorable into the Epidiolex update at AAN on April 22 despite the 34% rally since the last update in October. The firm notes its price target of $102 assumes a 66% probability-of-success for Epidiolex in Dravet/Lennox Gastaut. Changing the probabilities to 100% yields a target of $182, Leerink notes. It reiterates an Outperform rating on GW.
March 17, 2015
07:20 EDTGWPHBofA/Merrill to hold a conference
Smid Cap Conference 2015 is being held in Boston on March 17-18.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use